Review Article
Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review
Table 4
Phase 2 clinical trials of selumetinib in colorectal cancer.
| Study | Status | Results | NCT identifier |
| MK2206 and AZD6244 in patients with advanced colorectal cancer | Recruiting | Pending | NCT 01333475 | Phase 2 efficacy study of AZD6244 in colorectal cancer | Completed | Pending | NCT00514761 | Selumetinib + irinotecan as 2nd-line patients with KRAS and BRAF mutation | Recruiting | Pending | NCT01116271 |
|
|